Inhibitors of glucose transport and glycolysis as novel anticancer therapeutics

Table 3 Inhibitors of glucose transporters 1, glucose transporters 2, glucose transporters 3 and glucose transporters 4

Inhibitor	Target GLUT	Status	Ref.
WZB117	GLUT1	Animal study	Liu et al[28], 2012
STF-31	GLUT1	Animal study	Chan et al[240], 2011
Fasentin	GLUT1	In vitro	Wood et al[242], 2008
Apigenin	GLUT1	Phase II	NCT00609310
Genistein	GLUT1	Phase II/III	NCT00118040; NCT00584532
Oxime-based GLUT1 inhibitors	GLUT1	Animal study	Tuccinardi et al[255], 2013
Pyrrolidinone derived GLUT1 inhibitors	GLUT1	In vitro	Ulanovskaya et al[257], 2011
Phloretin	GLUT2	Animal study	Wu et al[258], 2009
Quercetin	GLUT2	Phase I	NCT01912820
DNA-damaging anticancer agents	GLUT3	In vitro	Watanabe et al[269], 2010
GSK-3 inhibitors	GLUT3	In vitro	Watanabe et al[270], 2012
Ritonavir	GLUT4	Phase I/II	NCT01009437; NCT01095094
Silibinin	GLUT4	Phase I/II	Flaig et al[280], 2007; NCT00487721

GLUTs: Glucose transporters.